June 18 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Thursday the U.S. health regulator has approved an expanded use of its pneumococcal vaccine for children and teenagers who ‌face a ...

What Is It, and Why Does It Matter? Capvaxive is a 21-valent pneumococcal conjugate vaccine (PCV21). It trains your immune system to recognize 21 types of Streptococcus pneumoniae, a germ that can ...

Please provide your email address to receive an email when new articles are posted on . Merck’s 21-valent pneumococcal vaccine Capvaxive was previously approved only for adults. The FDA expanded the ...

Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...

May 20 (Reuters) - Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up to 15-fold higher antibody levels ...

May 20 (Reuters) - Pfizer (PFE.N), opens new tab said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune response than its current shot, including up to 15-fold ...

Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common strains of pneumonia than currently available immunizations. The ...

Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% ...

After decades of developing vaccines to shield babies and adults from Streptococcus pneumonia infections, Pfizer is now taking another leap forward in its efforts to protect against one of the ...

A new Stanford study published Thursday marks a big step forward in the creation of a new kind of vaccine that offers protection against a range of infections at once. Traditionally, vaccines protect ...